Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cognitive performance in elderly people with elevated homocysteine (Hcy) levels. Methods: This multicenter, double-blind, randomized, placebo-controlled trial included 2,919 elderly participants (65 years and older) with Hcy levels between 12 and 50μmol/L. Participants received daily either a tablet with 400 mg folic acid and 500 mg vitamin B12 (B-vitamin group) or a placebo tablet. Both tablets contained 15 mg vitaminD3. Data were available for global cognitive functioning assessed by Mini-Mental State Examination (n =2,556), episodic memory (n =2,467), attention and working memory (n 5 759), information processing speed (n=731), and executive fu...
Background Low folate and raised homocysteine concentrations in blood are associated with poor cogni...
Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG...
Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG...
OBJECTIVE: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Item does not contain fulltextOBJECTIVE: We investigated the effects of 2-year folic acid and vitami...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background & aims: Mild cognitive impairment (MCI) patients are at risk of cognitive decline, while ...
BACKGROUND: Cognitive disorders in old age have a serious impact on the health and social aspects o...
Background Low folate and raised homocysteine concentrations in blood are associated with poor cogni...
Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG...
Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG...
OBJECTIVE: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Objective: We investigated the effects of 2-year folic acid and vitamin B12 supplementation on cogni...
Item does not contain fulltextOBJECTIVE: We investigated the effects of 2-year folic acid and vitami...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance o...
Background & aims: Mild cognitive impairment (MCI) patients are at risk of cognitive decline, while ...
BACKGROUND: Cognitive disorders in old age have a serious impact on the health and social aspects o...
Background Low folate and raised homocysteine concentrations in blood are associated with poor cogni...
Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG...
Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG...